Press-release for stocks for glaxf

Prices are updated after-hours

symbols : Glaxf source : Www.globenewswire.com

save search

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
Published: 2024-02-22 (Crawled : 18:00) - globenewswire.com
ALSMY | $1.51 -1.78% 650K

Manufacturing

| 17.74% | O: 0.0% H: 0.56% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -6.07% | O: 0.45% H: 0.24% C: -0.31%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -5.02% | O: 0.97% H: 0.0% C: 0.0%

Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
CNTA | $10.57 -1.95% -1.99% 110K

Manufacturing

| 96.26% | O: 1.25% H: 1.93% C: -2.99%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 9.73% | O: 0.25% H: 0.08% C: -0.8%
pharmaceuticals

Mersana Therapeutics Announces Changes in Leadership
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 14.58% | O: 0.12% H: 0.06% C: -0.55%
MRSN | $3.34 -5.11% -5.39% 1.3M

Health Technology

| 208.77% | O: 0.0% H: 9.65% C: 7.89%
therapeutics

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Published: 2023-08-21 (Crawled : 11:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| 18.82% | O: 0.0% H: 0.68% C: 0.68%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 14.88% | O: 0.26% H: 0.23% C: -0.03%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 40.51% | O: 2.54% H: 0.0% C: 0.0%
FOLD F | $10.35 -1.9% -1.93% 1.7M

Health Technology

| -18.85% | O: 0.71% H: 0.66% C: -1.56%
therapeutics financial simon

Erasca Further Strengthens Business Leadership with Two Key Promotions
Published: 2023-05-16 (Crawled : 12:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| 10.62% | O: -1.7% H: 3.06% C: 3.06%
ERAS | $1.795 -2.45% -2.51% 650K

| -34.8% | O: -0.68% H: 0.68% C: -3.4%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 7.67% | O: -0.9% H: 0.6% C: 0.05%
business

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
Published: 2023-05-10 (Crawled : 11:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| 9.78% | O: -1.66% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 8.64% | O: -0.03% H: 0.38% C: 0.25%
ZNTL | $12.55 -1.26% -1.27% 680K

Health Technology

| -44.28% | O: 2.59% H: 4.49% C: 4.23%
pharmaceuticals financial results

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| 6.15% | O: -4.57% H: 0.22% C: -1.98%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 7.29% | O: -0.03% H: 0.3% C: -2.63%
ZNTL | $12.55 -1.26% -1.27% 680K

Health Technology

| -41.67% | O: -0.23% H: 0.18% C: -1.43%
asco positive cancer meeting

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
Published: 2023-01-06 (Crawled : 12:20) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 14.85% | O: -0.44% H: 1.85% C: 1.72%
MRSN | $3.34 -5.11% -5.39% 1.3M

Health Technology

| -33.21% | O: 1.33% H: 5.9% C: 3.93%
expected therapeutics update

GlobalData Plc: North America Accounted for Highest Number of Social Anxiety Disorder Clinical Trials Conducted in 2022
Published: 2022-06-02 (Crawled : 16:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560

Health Technology

| 2.4% | O: 0.97% H: 0.19% C: -3.52%
NVSEF | $93.6375 6.88% 82K

Health Technology

| 25.41% | O: -0.31% H: 0.0% C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| 3.01% | O: -0.73% H: 0.12% C: 0.1%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -18.43% | O: 0.01% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -7.99% | O: 0.44% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M

Health Technology

| 3.24% | O: 0.56% H: 0.0% C: 0.0%
america trials social anxiety disorder

GlobalData Plc: Big Data Crucial for Business Strategy Across the Pharma Value Chain
Published: 2022-05-18 (Crawled : 15:20) - globenewswire.com
SAPGF | News | $176.75 -19.46% 1.1K

Technology Services

| 80.1% | O: -2.45% H: 0.63% C: -2.27%
SAP | News | $178.64 -0.72% 0.0% 1.5M

Technology Services

| 81.01% | O: -1.88% H: 0.0% C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -18.93% | O: 0.07% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -11.15% | O: -0.43% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -13.97% | O: 0.91% H: 0.0% C: 0.0%
pharma

Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
Published: 2022-03-21 (Crawled : 01:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -0.79% | O: 4.8% H: 4.09% C: 4.09%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -7.26% | O: 0.96% H: 0.0% C: 0.0%
ZLAB | News | $14.2 3.5% 3.38% 690K

Health Technology

| -61.42% | O: 10.34% H: 0.0% C: 0.0%
zejula pos positive results positive results phase 3 primec

GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
Published: 2022-01-11 (Crawled : 12:30) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -8.18% | O: 0.55% H: 0.0% C: 0.0%

Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -4.72% | O: 2.36% H: 0.46% C: 0.46%
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -3.77% | O: -0.48% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -8.4% | O: 0.86% H: 0.0% C: 0.0%
XNCR | $18.98 -0.47% -0.47% 470K

Health Technology

| -47.87% | O: -0.45% H: 0.0% C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K

Health Technology

| -85.14% | O: -4.59% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -7.59% | O: 0.22% H: 0.0% C: 0.0%
covid-19 treatment europe granted covid authorization grant

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
Published: 2021-12-07 (Crawled : 09:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| 0.4% | O: 5.22% H: 0.0% C: -1.25%
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| 0.64% | O: 3.63% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -5.42% | O: 0.14% H: 0.0% C: 0.0%
XNCR | $18.98 -0.47% -0.47% 470K

Health Technology

| -46.05% | O: -2.12% H: 4.74% C: 2.8%
VIR | $7.96 -3.52% -3.64% 880K

Health Technology

| -80.52% | O: -6.42% H: 8.6% C: 8.45%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -4.13% | O: -0.06% H: 0.0% C: 0.0%
preclinical sars-cov-2 pre-clinical

Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
Published: 2021-12-02 (Crawled : 08:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -1.19% | O: -0.05% H: 0.0% C: -1.97%
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -3.34% | O: 0.18% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -4.3% | O: 0.58% H: 0.5% C: -0.36%
VIR | $7.96 -3.52% -3.64% 880K

Health Technology

| -81.15% | O: 20.02% H: 0.19% C: -12.53%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -5.21% | O: -0.19% H: 0.0% C: 0.0%
preclinical sars-cov-2 pre-clinical

GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published: 2021-11-17 (Crawled : 12:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -2.23% | O: 1.43% H: 2.31% C: 2.27%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -6.54% | O: -0.28% H: 0.0% C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K

Health Technology

| -74.73% | O: 9.97% H: 4.0% C: -6.28%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -11.13% | O: -0.06% H: 0.0% C: 0.0%
covid treatment biotech technology iot covid-19

OraSure Technologies Appoints Two New Members to the Board of Directors
Published: 2021-11-08 (Crawled : 12:15) - globenewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology